A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for amyotrophic lateral sclerosis

Ann Logan, Zsuzsanna Nagy, Nicholas Barnes, Tony Belli, Valentina Di Pietro, Barbara Tavazzi, Giuseppe Lazzarino, Giacomo Lazzarino, Lars Bruce, Lennart I. Persson

Research output: Contribution to journalArticlepeer-review

8 Downloads (Pure)

Fingerprint

Dive into the research topics of 'A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Medicine & Life Sciences